Regulation 4 Amendment of regulation 8
In regulation 8(1)f1 (general interpretation), at the appropriate places insert—
““EAMS medicinal product” means a medicinal product that—
- (a)
has been included in the Early Access to Medicines Scheme by means of the licensing authority issuing an EAMS scientific opinion in respect of it; and
- (b)
remains in the scheme by virtue of the EAMS scientific opinion not ceasing to have effect in respect of it by virtue of regulation 167D;”;
““EAMS scientific opinion” is to be construed in accordance with regulation 167C(2)(b);”;
““EAMS scientific opinion holder” means the holder of a EAMS scientific opinion, and accordingly, is the person who places on the market the product to which the opinion relates;”;
““Early Access to Medicines Scheme” means the scheme of that name established and operated under regulation 167C(1);”; and
““EU Clinical Trials Regulation” means Regulation EU No. 536/2014 of the European Parliament and of the Council on clinical trials on medicinal products, and repealing Directive 2001/20/ECf2;”.